179 related articles for article (PubMed ID: 37704469)
1. Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS).
Stahl M; Bewersdorf JP; Xie Z; Porta MGD; Komrokji R; Xu ML; Abdel-Wahab O; Taylor J; Steensma DP; Starczynowski DT; Sekeres MA; Sanz G; Sallman DA; Roboz GJ; Platzbecker U; Patnaik MM; Padron E; Odenike O; Nimer SD; Nazha A; Majeti R; Loghavi S; Little RF; List AF; Kim TK; Hourigan CS; Hasserjian RP; Halene S; Griffiths EA; Gore SD; Greenberg P; Figueroa ME; Fenaux P; Efficace F; DeZern AE; Daver NG; Churpek JE; Carraway HE; Buckstein R; Brunner AM; Boultwood J; Borate U; Bejar R; Bennett JM; Wei AH; Santini V; Savona MR; Zeidan AM
Blood Rev; 2023 Nov; 62():101128. PubMed ID: 37704469
[TBL] [Abstract][Full Text] [Related]
2. Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS.
Kuendgen A; Nomdedeu M; Tuechler H; Garcia-Manero G; Komrokji RS; Sekeres MA; Della Porta MG; Cazzola M; DeZern AE; Roboz GJ; Steensma DP; Van de Loosdrecht AA; Schlenk RF; Grau J; Calvo X; Blum S; Pereira A; Valent P; Costa D; Giagounidis A; Xicoy B; Döhner H; Platzbecker U; Pedro C; Lübbert M; Oiartzabal I; Díez-Campelo M; Cedena MT; Machherndl-Spandl S; López-Pavía M; Baldus CD; Martinez-de-Sola M; Stauder R; Merchan B; List A; Ganster C; Schroeder T; Voso MT; Pfeilstöcker M; Sill H; Hildebrandt B; Esteve J; Nomdedeu B; Cobo F; Haas R; Sole F; Germing U; Greenberg PL; Haase D; Sanz G
Leukemia; 2021 Mar; 35(3):835-849. PubMed ID: 32595214
[TBL] [Abstract][Full Text] [Related]
3. Prognostication in myelodysplastic syndromes (neoplasms): Molecular risk stratification finally coming of age.
Xie Z; Chen EC; Stahl M; Zeidan AM
Blood Rev; 2023 May; 59():101033. PubMed ID: 36357283
[TBL] [Abstract][Full Text] [Related]
4. Recent Clinical and Molecular Advances for the Classification of Myelodysplastic Neoplasms.
DeZern AE; Greenberg PL
J Natl Compr Canc Netw; 2022 Dec; 20(12):1280-1283. PubMed ID: 36509078
[TBL] [Abstract][Full Text] [Related]
5. Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1
Bewersdorf JP; Xie Z; Bejar R; Borate U; Boultwood J; Brunner AM; Buckstein R; Carraway HE; Churpek JE; Daver NG; Porta MGD; DeZern AE; Fenaux P; Figueroa ME; Gore SD; Griffiths EA; Halene S; Hasserjian RP; Hourigan CS; Kim TK; Komrokji R; Kuchroo VK; List AF; Loghavi S; Majeti R; Odenike O; Patnaik MM; Platzbecker U; Roboz GJ; Sallman DA; Santini V; Sanz G; Sekeres MA; Stahl M; Starczynowski DT; Steensma DP; Taylor J; Abdel-Wahab O; Xu ML; Savona MR; Wei AH; Zeidan AM
Blood Rev; 2023 Jul; 60():101072. PubMed ID: 36934059
[TBL] [Abstract][Full Text] [Related]
6. Impact of the International Consensus Classification of myelodysplastic syndromes.
Zhang Y; Wu J; Xu Z; Qin T; Qu S; Pan L; Wang H; Sun Q; Li C; Jia Y; Cai W; Yan X; Gong J; Gao Q; Li B; Gale RP; Xiao Z
Br J Haematol; 2023 May; 201(3):443-448. PubMed ID: 36575970
[TBL] [Abstract][Full Text] [Related]
7. Comparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs de novo myelodysplastic syndromes: a report on behalf of the MDS Clinical Research Consortium.
Zeidan AM; Al Ali N; Barnard J; Padron E; Lancet JE; Sekeres MA; Steensma DP; DeZern A; Roboz G; Jabbour E; Garcia-Manero G; List A; Komrokji R
Leukemia; 2017 Jun; 31(6):1391-1397. PubMed ID: 28111463
[TBL] [Abstract][Full Text] [Related]
8. Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM).
Della Porta MG; Tuechler H; Malcovati L; Schanz J; Sanz G; Garcia-Manero G; Solé F; Bennett JM; Bowen D; Fenaux P; Dreyfus F; Kantarjian H; Kuendgen A; Levis A; Cermak J; Fonatsch C; Le Beau MM; Slovak ML; Krieger O; Luebbert M; Maciejewski J; Magalhaes SM; Miyazaki Y; Pfeilstöcker M; Sekeres MA; Sperr WR; Stauder R; Tauro S; Valent P; Vallespi T; van de Loosdrecht AA; Germing U; Haase D; Greenberg PL; Cazzola M
Leukemia; 2015 Jul; 29(7):1502-13. PubMed ID: 25721895
[TBL] [Abstract][Full Text] [Related]
9. Management of Patients with Lower-Risk Myelodysplastic Neoplasms (MDS).
Lucero J; Al-Harbi S; Yee KWL
Curr Oncol; 2023 Jun; 30(7):6177-6196. PubMed ID: 37504319
[TBL] [Abstract][Full Text] [Related]
10. The clinical, molecular, and prognostic features of the 2022 WHO and ICC classification systems for myelodysplastic neoplasms.
Khanna V; Lu R; Kumar J; Molina A; Stehr H; Spiteri E; Spinner M; Silva O; Fernandez-Pol S; Tan B; Greenberg PL
Leuk Res; 2024 Jan; 136():107433. PubMed ID: 38154193
[TBL] [Abstract][Full Text] [Related]
11. Validation of International Working Group response criteria in higher-risk myelodysplastic syndromes: A report on behalf of the MDS Clinical Research Consortium.
Komrokji RS; Al Ali NH; Sallman D; Padron E; DeZern AE; Barnard J; Roboz GJ; Garcia-Manero G; List A; Steensma DP; Sekeres MA
Cancer Med; 2021 Jan; 10(2):447-453. PubMed ID: 33350168
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the 2022 world health organization classification and international consensus classification in myelodysplastic syndromes/neoplasms.
Lee WH; Lin CC; Tsai CH; Tien FM; Lo MY; Tseng MH; Kuo YY; Yu SC; Liu MC; Yuan CT; Yang YT; Chuang MK; Ko BS; Tang JL; Sun HI; Chuang YK; Tien HF; Hou HA; Chou WC
Blood Cancer J; 2024 Apr; 14(1):57. PubMed ID: 38594285
[TBL] [Abstract][Full Text] [Related]
13. Improved risk stratification by the integration of the revised international prognostic scoring system with the myelodysplastic syndromes comorbidity index.
van Spronsen MF; Ossenkoppele GJ; Holman R; van de Loosdrecht AA
Eur J Cancer; 2014 Dec; 50(18):3198-205. PubMed ID: 25454415
[TBL] [Abstract][Full Text] [Related]
14. Cytogenetics and molecular genetics of myelodysplastic neoplasms.
Ning Y; Zhang Y; Kallen MA; Emadi A; Baer MR
Best Pract Res Clin Haematol; 2023 Dec; 36(4):101512. PubMed ID: 38092472
[TBL] [Abstract][Full Text] [Related]
15. Morphologic Characteristics of Myelodysplastic Syndromes.
Yuen LD; Hasserjian RP
Clin Lab Med; 2023 Dec; 43(4):577-596. PubMed ID: 37865504
[TBL] [Abstract][Full Text] [Related]
16. [Current state of treatment for myelodysplastic syndromes].
Ichikawa M
Rinsho Ketsueki; 2023; 64(9):988-997. PubMed ID: 37793875
[TBL] [Abstract][Full Text] [Related]
17. Cytogenetics in the management of myelodysplastic neoplasms (myelodysplastic syndromes, MDS): Guidelines from the groupe francophone de cytogénétique hématologique (GFCH).
Auger N; Douet-Guilbert N; Quessada J; Theisen O; Lafage-Pochitaloff M; Troadec MB
Curr Res Transl Med; 2023; 71(4):103409. PubMed ID: 38091642
[TBL] [Abstract][Full Text] [Related]
18. Prognostic relevance of morphological classification models for myelodysplastic syndromes in an era of the revised International Prognostic Scoring System.
van Spronsen MF; Ossenkoppele GJ; Westers TM; van de Loosdrecht AA
Eur J Cancer; 2016 Mar; 56():10-20. PubMed ID: 26798967
[TBL] [Abstract][Full Text] [Related]
19. Molecular landscape of myelodysplastic neoplasms in disease classification and prognostication.
Maggioni G; Della Porta MG
Curr Opin Hematol; 2023 Mar; 30(2):30-37. PubMed ID: 36728601
[TBL] [Abstract][Full Text] [Related]
20. Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study.
Steensma DP; Abedi M; Bejar R; Cogle CR; Foucar K; Garcia-Manero G; George TI; Grinblatt D; Komrokji R; Ma X; Maciejewski J; Pollyea DA; Savona MR; Scott B; Sekeres MA; Thompson MA; Swern AS; Nifenecker M; Sugrue MM; Erba H
BMC Cancer; 2016 Aug; 16():652. PubMed ID: 27538433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
